Alexandra Snyder Charen

List of Publications by Year
in descending order

44 papers	22,964 citations	172207 29 h-index	288905 40 g-index
52 all docs	52 docs citations	52 times ranked	30208 citing authors

#	Article	IF	Citations
1	Germline HLA landscape does not predict efficacy of pembrolizumab monotherapy across solid tumor types. Immunity, 2022, 55, 56-64.e4.	6.6	19
2	Tumor mutational burden predicts the efficacy of pembrolizumab monotherapy: a pan-tumor retrospective analysis of participants with advanced solid tumors. , 2022, 10, e003091.		67
3	Understanding the impact of chemotherapy on the immune landscape of high-grade serous ovarian cancer. Gynecologic Oncology Reports, 2022, 39, 100926.	0.3	10
4	Neoantigen-specific CD8 T cell responses in the peripheral blood following PD-L1 blockade might predict therapy outcome in metastatic urothelial carcinoma. Nature Communications, 2022, 13, 1935.	5.8	37
5	Current strategies for intratumoural immunotherapy â€“ Beyond immune checkpoint inhibition. European Journal of Cancer, 2021, 157, 493-510.	1.3	28
6	Phase II study of atezolizumab in combination with bevacizumab in patients with advanced cervical cancer. , 2020, 8, e001126.		54
7	Integrated Multi-Tumor Radio-Genomic Marker of Outcomes in Patients with High Serous Ovarian Carcinoma. Cancers, 2020, 12, 3403.	1.7	24
8	Unraveling tumorâ€“immune heterogeneity in advanced ovarian cancer uncovers immunogenic effect of chemotherapy. Nature Genetics, 2020, 52, 582-593.	9.4	136
9	Comprehensive T cell repertoire characterization of non-small cell lung cancer. Nature Communications, 2020, 11, 603.	5.8	140
10	Use of Circulating Tumor DNA for Cancer Immunotherapy. Clinical Cancer Research, 2019, 25, 6909-6915.	3.2	34
11	TOX is a critical regulator of tumour-specific T cell differentiation. Nature, 2019, 571, 270-274.	13.7	697
12	Toward a comprehensive view of cancer immune responsiveness: a synopsis from the SITC workshop. , 2019, 7, 131.		64
13	Early disease progression and treatment discontinuation in patients with advanced ovarian cancer receiving immune checkpoint blockade. Gynecologic Oncology, 2019, 152, 251-258.	0.6	33
14	Immunogenomics. , 2019, , 99-110.		0
15	Genomic Features of Response to Combination Immunotherapy in Patients with Advanced Non-Small-Cell Lung Cancer. Cancer Cell, 2018, 33, 843-852.e4.	7.7	827
16	Cancer-Germline Antigen Expression Discriminates Clinical Outcome to CTLA-4 Blockade. Cell, 2018, 173, 624-633.e8.	13.5	113
17	Global Cancer Transcriptome Quantifies Repeat Element Polarization between Immunotherapy Responsive and T Cell Suppressive Classes. Cell Reports, 2018, 23, 512-521.	2.9	90
18	Genomic correlates of response to immune checkpoint therapies in clear cell renal cell carcinoma. Science, 2018, 359, 801-806.	6.0	898

#	Article	IF	Citations
19	Alterations in DNA Damage Response and Repair Genes as Potential Marker of Clinical Benefit From PD-1/PD-L1 Blockade in Advanced Urothelial Cancers. Journal of Clinical Oncology, 2018, 36, 1685-1694.	0.8	399
20	Molecular Determinants of Response to Antiâ€“Programmed Cell Death (PD)-1 and Antiâ€“Programmed Death-Ligand 1 (PD-L1) Blockade in Patients With Nonâ€“Small-Cell Lung Cancer Profiled With Targeted Next-Generation Sequencing. Journal of Clinical Oncology, 2018, 36, 633-641.	0.8	1,109
21	A multifactorial model of T cell expansion and durable clinical benefit in response to a PD-L1 inhibitor. PLoS ONE, 2018, 13, e0208422.	1.1	14
22	Clinical Utility of Prospective Molecular Characterization in Advanced Endometrial Cancer. Clinical Cancer Research, 2018, 24, 5939-5947.	3.2	100
23	Chemotherapy weakly contributes to predicted neoantigen expression in ovarian cancer. BMC Cancer, 2018, 18, 87.	1.1	33
24	A novel representation of inter-site tumour heterogeneity from pre-treatment computed tomography textures classifies ovarian cancers by clinical outcome. European Radiology, 2017, 27, 3991-4001.	2.3	92
25	Somatic Mutations and Neoepitope Homology in Melanomas Treated with CTLA-4 Blockade. Cancer Immunology Research, 2017, 5, 84-91.	1.6	126
26	Heterogeneous Tumor-Immune Microenvironments among Differentially Growing Metastases in an Ovarian Cancer Patient. Cell, 2017, 170, 927-938.e20.	13.5	368
27	Making It Personal: Neoantigen Vaccines in Metastatic Melanoma. Immunity, 2017, 47, 221-223.	6.6	31
28	Contribution of systemic and somatic factors to clinical response and resistance to PD-L1 blockade in urothelial cancer: An exploratory multi-omic analysis. PLoS Medicine, 2017, 14, e1002309.	3.9	256
29	OncoKB: A Precision Oncology Knowledge Base. JCO Precision Oncology, 2017, 2017, 1-16.	1.5	1,266
30	Successful Treatment of a Patient with Glioblastoma and a Germline POLE Mutation: Where Next?. Cancer Discovery, 2016, 6, 1210-1211.	7.7	14
31	Acquired resistance to immunotherapy and future challenges. Nature Reviews Cancer, 2016, 16, 121-126.	12.8	353
32	Clonal neoantigens elicit T cell immunoreactivity and sensitivity to immune checkpoint blockade. Science, 2016, 351, 1463-1469.	6.0	2,445
33	Cancer Neoantigens and Applications for Immunotherapy. Clinical Cancer Research, 2016, 22, 807-812.	3.2	188
34	Genetic Basis for Clinical Response to CTLA-4 Blockade in Melanoma. New England Journal of Medicine, 2015, 373, 1984-1984.	13.9	166
35	Immunogenic peptide discovery in cancer genomes. Current Opinion in Genetics and Development, 2015, 30, 7-16.	1.5	63
36	Toward understanding and exploiting tumor heterogeneity. Nature Medicine, 2015, 21, 846-853.	15.2	604

#	Article	IF	Citations
37	Mutational landscape determines sensitivity to PD-1 blockade in nonâ€“small cell lung cancer. Science, 2015, 348, 124-128.	6.0	6,756
38	Genetics and immunology: reinvigorated. OncoImmunology, 2015, 4, e1029705.	2.1	7
39	Genetic Basis for Clinical Response to CTLA-4 Blockade. New England Journal of Medicine, 2015, 372, 783-783.	13.9	85
40	Inhibiting DNA Methylation Causes an Interferon Response in Cancer via dsRNA Including Endogenous Retroviruses. Cell, 2015, 162, 974-986.	13.5	1,408
41	Could microbial therapy boost cancer immunotherapy?. Science, 2015, 350, 1031-1032.	6.0	36
42	Liver-directed conversion therapy in metastatic colon cancer. Journal of Gastrointestinal Oncology, 2015, 6, 322-8.	0.6	1
43	Genetic Basis for Clinical Response to CTLA-4 Blockade in Melanoma. New England Journal of Medicine, 2014, 371, 2189-2199.	13.9	3,753
44	Perspectives on Immunotherapy in Prostate Cancer and Solid Tumors: Where Is the Future?. Seminars in Oncology, 2013, 40, 347-360.	0.8	13